No label defined (Q32215)
Jump to navigation
Jump to search
No description defined
- The Impact of a Breast Cancer Risk Assessment on the Decision for Gender-Affirming Chest Masculinization Surgery in Transgender and Gender-Diverse Individuals: A Pilot Single-Arm Educational Intervention Trial.
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
No description defined |
|
Statements
Persons assigned female or intersex at birth and identify as transgender and/or gender-diverse (TGD) may undergo gender-affirming chest masculinization surgery (GACMS); however, GACMS is not considered equivalent to risk-reducing mastectomies (RRM). (English)
BACKGROUND (English)
© 2024. Society of Surgical Oncology. (English)
2024
This study aimed to estimate the prevalence of elevated breast cancer (BC) risk in TGD persons, compare self-perceived versus calculated risk, and determine how risk impacts the decision for GACMS versus RRM. (English)
BACKGROUND (English)
© 2024. Society of Surgical Oncology. (English)
2024
A prospective single-arm pilot educational intervention trial was conducted in individuals assigned female or intersex at birth, age ≥ 18 years, considering GACMS, without a BC history or a known pathogenic variant. (English)
METHODS (English)
© 2024. Society of Surgical Oncology. (English)
2024
BC risk was calculated using the Tyrer-Cuzik (all) and Gail models (age ≥ 35 years). (English)
METHODS (English)
© 2024. Society of Surgical Oncology. (English)
2024
Elevated risk was defined as ≥ 17%. (English)
METHODS (English)
© 2024. Society of Surgical Oncology. (English)
2024
Twenty-five (N = 25) participants were enrolled with a median age of 24.0 years (interquartile range, IQR 20.0-30.0 years). (English)
RESULTS (English)
© 2024. Society of Surgical Oncology. (English)
2024
All were assigned female sex at birth, most (84%) were Non-Hispanic (NH)-White, 48% identified as transgender and 40% as nonbinary, and 52% had a first- and/or second-degree family member with BC. (English)
RESULTS (English)
© 2024. Society of Surgical Oncology. (English)
2024
Thirteen (52%) had elevated risk (prevalence 95% confidence interval (CI) 31.3-72.2%). (English)
RESULTS (English)
© 2024. Society of Surgical Oncology. (English)
2024
Median self-perceived risk was 12% versus 17.5% calculated risk (p = 0.60). (English)
RESULTS (English)
© 2024. Society of Surgical Oncology. (English)
2024
Of the 13 with elevated risk, 5 (38.5%) underwent/are scheduled to undergo GACMS, 3 (23%) of whom underwent/are undergoing RRM. (English)
RESULTS (English)
© 2024. Society of Surgical Oncology. (English)
2024
Over half of the cohort had elevated risk, and most of those who moved forward with surgery chose to undergo RRM. (English)
CONCLUSIONS (English)
© 2024. Society of Surgical Oncology. (English)
2024
A BC risk assessment should be performed for TGD persons considering GACMS. (English)
CONCLUSIONS (English)
© 2024. Society of Surgical Oncology. (English)
2024
Future work is needed to examine BC incidence and collect patient-reported outcomes. (English)
CONCLUSIONS (English)
© 2024. Society of Surgical Oncology. (English)
2024
Trial Registration Number ClinicalTrials.gov (No. (English)
CONCLUSIONS (English)
© 2024. Society of Surgical Oncology. (English)
2024
NCT06239766). (English)
CONCLUSIONS (English)
© 2024. Society of Surgical Oncology. (English)
2024
Chandler S (English)
Cortina (English)
CS
Anna (English)
Purdy (English)
A
Ruta (English)
Brazauskas (English)
R
Samantha M (English)
Stachowiak (English)
SM
Jessica (English)
Fodrocy (English)
J
Kristen A (English)
Klement (English)
KA
Sarah E (English)
Sasor (English)
SE
Kate B (English)
Krucoff (English)
KB
Kevin (English)
Robertson (English)
K
Jamie (English)
Buth (English)
J
Annie E B (English)
Lakatos (English)
AEB
Andrew E (English)
Petroll (English)
AE
Erin L (English)
Doren (English)
EL
7 October 2024
4 October 2024
<b>DISCLOSURE</b> The authors have no disclosures to report. (English)